Comparison
Company
Score
Quality
Valuation
Financial
Technical
Why is ABVC BioPharma, Inc. ?
Unrated Stock - No Analysis Available
Quality key factors
Factor
Value
Sales Growth (5y)
3.71%
EBIT Growth (5y)
0.47%
EBIT to Interest (avg)
-6.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.37
Sales to Capital Employed (avg)
0.06
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
5.05%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.87
EV to EBIT
-8.03
EV to EBITDA
-8.97
EV to Capital Employed
2.66
EV to Sales
36.06
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-33.10%
ROE (Latest)
-36.79%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Technical Movement
9What is working for the Company
NET SALES(HY)
At USD 0.8 MM has Grown at 57.17%
RAW MATERIAL COST(Y)
Fallen by -21.42% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at 13.88 %
INVENTORY TURNOVER RATIO(HY)
Highest at 82.04 times
-10What is not working for the Company
PRE-TAX PROFIT(Q)
At USD -1.29 MM has Fallen at -42.54%
NET PROFIT(Q)
At USD -1.25 MM has Fallen at -52.73%
Here's what is working for ABVC BioPharma, Inc.
Net Sales
At USD 0.8 MM has Grown at 57.17%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Debt-Equity Ratio
Lowest at 13.88 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Inventory Turnover Ratio
Highest at 82.04 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by -21.42% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for ABVC BioPharma, Inc.
Pre-Tax Profit
At USD -1.29 MM has Fallen at -42.54%
over average net sales of the previous four periods of USD -0.9 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -1.25 MM has Fallen at -52.73%
over average net sales of the previous four periods of USD -0.82 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)






